1104502--4/15/2010--ACRONGENOMICS

related topics

{stock, price, share}

{interest, director, officer}

{condition, economic, financial}

{investment, property, distribution}

{control, financial, internal}

{acquisition, growth, future}

{property, intellectual, protect}

{personnel, key, retain}

Risks Related to our Financial Condition We have not earned any revenues since our incorporation and only have a limited operating history in our current business, which raise doubt about our ability to continue as a going concern. Our independent auditors have expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing. Risks Related to our Business The global financial crisis has had, and may continue to have, an impact on our business and financial condition. The Share Exchange Agreement with Vardisto may not complete and we may not obtain an interest in the development of the potential cholesterol-lowering agent. We need to raise additional financing to support the research and development of future business but we cannot be sure that we will be able to obtain additional financing on terms favorable to us when needed. If we are unable to obtain additional financing to meet our needs, our operations may be adversely affected or terminated. Molecular Vision may be subject to intellectual property litigation such as patent infringement claims, which could adversely affect our business. Because some of our officers and directors are located in non-U.S. jurisdictions, you may have no effective recourse against the management for misconduct and may not be able to enforce judgment and civil liabilities against our officers, directors, experts and agents. If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted. Investment Company Act of 1940 Our ability to hire and retain qualified personnel will be an important factor in the success of our business and a failure to hire and retain key personnel may result in our inability to manage and implement our business plan. Our disclosure controls and procedures and internal control over financial reporting were proven not effective, which may cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public. Risks Related to our Common Shares The recent weakening of economic conditions around the world could have harmful effects on our company. If these harmful effects cause us to cease our development of medical technologies, then our shareholders will likely lose their entire investment in our company. Because we do not intend to pay any dividends on our common stock, investors seeking dividend income or liquidity should not purchase shares of our common stock. A decline in the price of our common stock could affect our ability to raise further working capital and adversely impact our ability to continue operations If we issue additional shares in the future, it will result in the dilution of our existing shareholders. Trading of our stock may be restricted by the Securities Exchange Commission s penny stock regulations, which may limit a stockholder s ability to buy and sell our stock. The Financial Industry Regulatory Authority, or FINRA, has adopted sales practice requirements which may also limit a stockholder s ability to buy and sell our stock. Our common stock is illiquid and the price of our common stock may be negatively impacted by factors which are unrelated to our operations.

Full 10-K form ▸

1104502--4/15/2010--ACRONGENOMICS_INC